
    
      The impact of SGLT-2 inhibition on endogenous glucose production and plasma glucagon levels
      will be compared measured in patients with ESRD.The secondary endpoints are the mean
      difference in plasma glucose, insulin, c-peptide, FFA,GH, epinephrine, norepinephrine,
      cortisol and blood pressure during the last hour of the experiment between empagliflozin
      versus placebo administration in patients.
    
  